Biotech Funding And IPO Temperature Check With Create Medicine's Allan Shaw
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides lower interest rates might bring generalist investors back into the sector.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Setting The Stakes For Biotech
- 1:29Big-Deal MA And Ecosystem Effects
- 3:50IPO Backlog And What Unlocks It
- 6:20Crossovers, Mutual Funds, And Allocation
- 9:10Avoiding Broken Issues And Rate Dynamics
- 12:00Buyout Versus IPO: Value And Returns
- 15:20Post-IPO Value: Liquidity And Currency
- 18:10Managing Expectations And Milestones
- 21:10Timing Catalysts Around An IPO
- 24:00Generalists Returning And What It Takes
- 27:00Hot Modalities: ADCs And Radiopharma
- 29:10Staying Relevant With Catalyst Cadence
- 31:30Collaborate Strategically, Not As A CRO
- 34:00Collaboration Tradeoffs And Opportunity Cost
- 37:00Building A Partnership Pipeline
- 40:00Alternative Financing And Spending Discipline
- 43:10Prioritising Programs For Impact
- 46:00Key Risks: FDA, Capital, And China
- 49:30Global Speed Advantage And Offshore Trials
- 53:10Closing Thoughts And Where To Subscribe